Review article · 2017 · Open access

Engineering Natural Killer Cells for Cancer Immunotherapy

Katayoun Rezvani, Rayne Helen Rouce, Enli Liu, Elizabeth J. Shpall

Molecular Therapy, 25(8), 1769–1781 · Published 28 June 2017 · DOI 10.1016/j.ymthe.2017.06.012

Open PDFView at the publisherCite this paper

In brief

“Engineering Natural Killer Cells for Cancer Immunotherapy” is a 2017 review article by Katayoun Rezvani and 3 co-authors, published in Molecular Therapy. OpenAlex counts 474 citations as of 21 November 2026, which puts it in the top 2% of works published in 2017 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Therapy.

Citations
474
Most cited in
2021 (83)
Field-weighted impact
4.92
References
144
Authors
4

Abstract

The past several years have seen tremendous advances in the engineering of immune effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have been used extensively to redirect the specificity of autologous T cells against hematological malignancies with striking clinical results, studies of CAR-modified natural killer (NK) cells have been largely preclinical. In this review, we focus on recent advances in NK cell engineering, particularly on preclinical evidence suggesting that NK cells may be as effective as T cells in recognizing and killing targets after genetic modification. We will discuss strategies to introduce CARs into both primary NK cells and NK cell lines in an effort to provide antigen specificity, the challenges of manufacturing engineered NK cells, and evidence supporting the effectiveness of this approach from preclinical and early-phase clinical studies using CAR-engineered NK cells. CAR-NK cells hold great promise as a novel cellular immunotherapy against refractory malignancies. Notably, NK cells can provide an "off-the-shelf" product, eliminating the need for a personalized and patient-specific product that plagues current CAR-T cell therapies. The ability to more potently direct NK cell-mediated cytotoxicity against refractory tumors through the expression of CAR is likely to contribute to the recent paradigm shift in cancer treatment.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017). Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25(8), 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012

MLA 9

Rezvani, Katayoun, et al. “Engineering Natural Killer Cells for Cancer Immunotherapy.” Molecular Therapy, vol. 25, no. 8, 2017, pp. 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012.

Chicago

Rezvani, Katayoun, Rayne Helen Rouce, Enli Liu, and Elizabeth J. Shpall. 2017. “Engineering Natural Killer Cells for Cancer Immunotherapy.” Molecular Therapy 25 (8): 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012.

Harvard

Rezvani, K. et al. (2017) ‘Engineering Natural Killer Cells for Cancer Immunotherapy’, Molecular Therapy, 25(8), pp. 1769–1781. doi:10.1016/j.ymthe.2017.06.012.

IEEE

K. Rezvani, R. H. Rouce, E. Liu, and E. J. Shpall, “Engineering Natural Killer Cells for Cancer Immunotherapy,” Molecular Therapy, vol. 25, no. 8, pp. 1769–1781, 2017, doi: 10.1016/j.ymthe.2017.06.012.

BibTeX

@article{rezvani2017engineering,
  title     = {{Engineering Natural Killer Cells for Cancer Immunotherapy}},
  author    = {Rezvani, Katayoun and Rouce, Rayne Helen and Liu, Enli and Shpall, Elizabeth J.},
  journal   = {Molecular Therapy},
  year      = {2017},
  volume    = {25},
  number    = {8},
  pages     = {1769--1781},
  doi       = {10.1016/j.ymthe.2017.06.012},
  url       = {https://doi.org/10.1016/j.ymthe.2017.06.012}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201777
20183030
20196161
20206666
20218383
20225555
20234848
20244545
20255252
20262727

Its field-weighted citation impact is 4.92: it has been cited 4.92 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • natural killer cells
  • CAR-NK cells
  • chimeric antigen receptor
  • NK cell engineering
  • cellular immunotherapy
  • off-the-shelf cell products
  • NK cell cytotoxicity
  • NK cell lines

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017). Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25(8), 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012

How many times has this paper been cited?

474 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Katayoun Rezvani, Rayne Helen Rouce, Enli Liu, Elizabeth J. Shpall.

What is the DOI of this paper?

10.1016/j.ymthe.2017.06.012, permanently at https://doi.org/10.1016/j.ymthe.2017.06.012. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.